A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B)
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to investigate the safety and tolerability of the
anti-vascular endothelial growth factor receptor-2 (anti-VEGFR-2) monoclonal antibody
Ramucirumab (IMC-1121B) in combination with irinotecan, levofolinate, and 5-fluorouracil
(FOLFIRI) in Japanese participants with advanced colorectal carcinoma (CRC).